No abstract available
MeSH terms
-
Benzhydryl Compounds / adverse effects
-
Benzhydryl Compounds / therapeutic use
-
Canagliflozin / adverse effects
-
Canagliflozin / therapeutic use
-
Diabetes Mellitus, Type 1 / drug therapy
-
Diabetes Mellitus, Type 1 / metabolism
-
Diabetes Mellitus, Type 2 / drug therapy
-
Diabetes Mellitus, Type 2 / metabolism
-
Diabetic Ketoacidosis / chemically induced*
-
Diabetic Ketoacidosis / diagnosis
-
Glucosides / adverse effects
-
Glucosides / therapeutic use
-
Humans
-
Hypoglycemic Agents / adverse effects*
-
Hypoglycemic Agents / therapeutic use
-
Sodium-Glucose Transporter 2 / metabolism
-
Sodium-Glucose Transporter 2 Inhibitors*
Substances
-
Benzhydryl Compounds
-
Glucosides
-
Hypoglycemic Agents
-
Sodium-Glucose Transporter 2
-
Sodium-Glucose Transporter 2 Inhibitors
-
Canagliflozin
-
empagliflozin
-
6-((4-ethylphenyl)methyl)-3',4',5',6'-tetrahydro-6'-(hydroxymethyl)spiro(isobenzofuran-1(3H),2'-(2H)pyran)-3',4',5'-triol